文献速递胃肠外科肝胆胰外科围术期管理与 ERAS

腹腔镜袖状胃切除术对Child-A级NASH相关肝硬化纤维化分期的影响

Impact of laparoscopic sleeve gastrectomy on fibrosis stage in patients with child-A NASH-related cirrhosis.
PubMed 文献 · Surg Endosc · 2020-03-09

该前瞻性研究纳入132例Child-A级NASH相关肝硬化合并病态肥胖拟行LSG患者,最终71例完成30个月随访。术后中位NAS从6显著降至3,26.8%患者纤维化消退至F2,40.8%至F3,且纤维化改善与更多体重减轻显著相关。LSG可能安全且长期改善肥胖及肝脏病变。

要点

  • LSG在Child-A级NASH相关肝硬化患者中可能安全,并带来显著体重减轻。
  • 术后30个月纤维化分期改善,26.8%消退至F2,40.8%至F3。
  • 纤维化改善与更大体重减轻显著相关(p<0.001),男性更常见(p=0.007)。

核心结论

  • 在Child-A级NASH相关肝硬化患者中,LSG可能是治疗病态肥胖的安全方法,并对肥胖和肝脏病变有长期益处。

研究设计与样本

  • 前瞻性研究纳入132例Child-A级NASH相关肝硬化合并病态肥胖拟行LSG患者,术前评估及楔形活检,术后30个月超声引导下粗针肝活检,仅71例完成随访。

主要发现

  • 术后30个月中位NAS从6(1-8)显著降至3(0-6)。
  • 纤维化评分消退至F2者19例(26.8%),至F3者29例(40.8%)。
  • 纤维化改善者体重减轻显著更多(p < 0.001),且男性更常见(p = 0.007)。
  • 术后30个月,临界NASH者53.8%完全缓解,疑似NASH者36.8%完全缓解,NASH者44.7%改善。
  • 脂肪变性改善者占74.6%(p < 0.001)。

临床怎么用

  • 对于Child-A级NASH相关肝硬化合并病态肥胖患者,LSG可考虑作为减重和改善肝脏病变的选项。

局限性

  • 最终仅71例(53.8%)完成30个月随访,存在失访偏倚可能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Bariatric surgery can improve non-alcoholic fatty liver disease (NAFLD). Yet data on the effect on fibrosis are insufficient and controversial. This work endeavored to evaluate the safety of laparoscopic sleeve gastrectomy (LSG) in cases that have compensated non-alcoholic steatohepatitis (NASH)-related cirrhosis and its impact on fibrosis stage. METHODS: The current prospective work involved 132 cases with Child-A NASH-related cirrhosis suffering from morbid obesity scheduled for LSG. They were subjected to preoperative assessment, wedge biopsy, and ultrasound-guided true-cut liver biopsy after 30 months. Patients were included if proved to have F4 fibrosis initially. The liver condition was assessed based on the NALFD Activity Score (NAS). The primary outcome measure was the impact of LSG on fibrosis stage and its relation to weight loss. RESULTS: The analysis included only 71 patients who completed the 30-month follow-up period. By the end of the follow-up interval, there was a substantial weight loss with a reasonable resolution of comorbidities. The median NAS decreased significantly from 6 (1-8) to 3 (0-6) after surgery. Fibrosis score regressed to F2 in 19 patients (26.8%) and F3 in 29 (40.8%). Patients with improved scores had a significantly higher amount of weight loss (p < 0.001). Improvement was more frequent in males (p = 0.007). By 30 months after treatment, 53.8% of cases with borderline NASH and 36.8% of those with probable NASH showed complete resolution, and 44.7% of patients with NASH showed improvement. Steatosis improved in 74.6% of patients (p < 0.001). CONCLUSION: In patients with NASH-related liver cirrhosis of Child class A, LSG may be a secure approach for the management of morbid obesity. It has a long-term benefit for both obesity and liver condition with significant improvement of steatosis, steatohepatitis, and fibrosis.

来源:Surg Endosc,查看原文。版权归原作者所有。

引用

  1. Salman MA, Mikhail HMS, Nafea MA, et al. Impact of laparoscopic sleeve gastrectomy on fibrosis stage in patients with child-A NASH-related cirrhosis. Surg Endosc. 2020. PMID: 32152677. doi:10.1007/s00464-020-07498-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。